Group 1 - The company announced the suspension of subscription services for the Yinhua CSI Infrastructure ETF Fund starting from May 26, 2025, while redemption and conversion services will continue to operate normally [1] - The company has signed a sales agency agreement with Western Securities to add it as a broker for several ETFs, effective May 26, 2025 [2] - The company has also signed a sales agency agreement with Dongwu Securities to include it as a broker for the Yinhua CSI Mainland Low-Carbon Economy ETF, effective May 26, 2025 [3]

Group 1 - The core viewpoint of the article highlights the increasing volatility in the overseas bond market, particularly with the 30-year U.S. Treasury yield surpassing 5% and Japan's bond yields rising due to weak auction results [1][2] - The U.S. bond market is facing multiple negative factors, including a downgrade of the U.S. sovereign credit rating by Moody's, concerns over the fiscal deficit, and weak demand for U.S. Treasuries, which are pushing long-term yields higher [2][3] - Japan's bond yields are also rising sharply due to a significant imbalance in supply and demand, exacerbated by fiscal expansion and a relatively tight monetary policy from the Bank of Japan [2][3] Group 2 - In contrast to the overseas markets, China's bond market remains stable, with the 10-year government bond yield fluctuating within a narrow range of 1.68% to 1.72% [3][4] - The People's Bank of China has implemented a moderately loose monetary policy to support liquidity, including a recent reserve requirement ratio cut and substantial medium-term lending facility operations [3][4] - Analysts expect the Chinese bond market to continue its narrow fluctuations, with the 10-year government bond yield projected to remain between 1.65% and 1.70% in the short term [4]

西部证券股份有限公司2025年度第四期短期融资券于2025年5月20日发行，缴款日为2025年5月21日。此 次短期融资券简称25西部证券CP004，代码072510085，期限365天，起息日2025年5月21日，兑付日 2026年5月21日。计划发行量与实际发行总额均为15亿元人民币，发行价格100元/张，票面利率1.74%。 相关文件已在中国货币网和上海清算所网站上公布。 2024年度第七期短期融资券兑付完成的公告 交易信息汇总 5月23日，西部证券的资金流向显示，主力资金净流出1752.31万元；游资资金净流出178.43万元；而散 户资金则呈现出净流入的趋势，净流入额为1930.74万元。 公司公告汇总2025年度第四期短期融资券发行结果公告 截至2025年5月23日收盘，西部证券(002673)报收于7.36元，下跌1.87%，换手率0.68%，成交量27.75万 手，成交额2.07亿元。 当日关注点 西部证券股份有限公司2024年度第七期短期融资券于2024年6月19日发行，发行金额为20亿元人民币， 票面利率2.09%，发行期限336天，兑付日为2025年5月22日。公司在2025年5月22日 ...

Core Viewpoint - The company, Yinhua Fund Management Co., Ltd., announces a fee discount activity for its Yinhua Zhongzhai 1-3 Year Agricultural Development Bank Bond Index Securities Investment Fund starting from May 26, 2025, to meet investor demand [1]. Group 1: Fee Discount Activity - From May 26, 2025, investors can purchase the fund through participating distribution agencies with fee discounts based on specific arrangements by the agencies, while fixed fee rates will remain unchanged [2]. - The fee discount activity is limited to the front-end model for off-site transactions, and any changes to the activity or rules will be communicated through the respective distribution agencies [2]. - The interpretation rights of the fee discount activity content belong to the participating distribution agencies, and the rules and processes for business handling will follow their arrangements [2]. Group 2: Additional Distribution Agencies - Starting from May 26, 2025, the company will add Western Securities Co., Ltd. and Dongwu Securities Co., Ltd. as distribution agents for several of its exchange-traded funds (ETFs) [9][10]. - The specific ETFs include Yinhua Guozheng Free Cash Flow ETF, Yinhua Zhongzheng A50 ETF, Yinhua Zhongzheng Film Theme ETF, Yinhua Zhongzheng Innovative Drug Industry ETF, Yinhua Zhongzheng 5G Communication Theme ETF, Yinhua Hu-Shen 300 Value ETF, Yinhua Zhongzheng 500 Value ETF, and Yinhua Zhongzheng National New Central Enterprise Technology Leading ETF [9][10].

Core Viewpoint - The article discusses the controversy surrounding Huaxi Biological, a leading player in the medical aesthetics industry, which publicly refuted claims made by nine brokerage firms regarding the obsolescence of hyaluronic acid, asserting that these claims mislead the market and harm the industry [2][5][13]. Group 1: Industry Response - Huaxi Biological received support from two industry associations before making its statement and has reported the misleading content to the China Securities Regulatory Commission (CSRC) [2][12]. - Following Huaxi's public rebuttal, some brokerage firms have deleted their reports, and certain institutions have issued apologies to the company [2][12]. - The brokerage reports in question were primarily focused on the emerging concept of recombinant collagen, which Huaxi argues is being promoted at the expense of hyaluronic acid [5][13]. Group 2: Misleading Claims - Huaxi Biological criticized the brokerage reports for making misleading comparisons between hyaluronic acid and recombinant collagen, claiming that these reports lacked scientific basis and were driven by speculative capital [5][13]. - The company highlighted that the reports suggested hyaluronic acid was inferior to recombinant collagen in terms of safety and efficacy, which Huaxi disputes, stating that such conclusions are not supported by scientific evidence [5][31]. Group 3: Regulatory and Compliance Issues - The article raises concerns about the compliance of the brokerage reports, suggesting that they may not have adhered to the necessary standards for objectivity and scientific backing [20][21]. - Industry experts indicate that the reports should have included relevant data to support their claims, and the lack of such data could lead to regulatory scrutiny [21][22]. - The ongoing regulatory environment is described as increasingly stringent, with past instances of penalties for brokerage firms due to similar issues [26][27]. Group 4: Scientific Basis of Claims - Huaxi Biological argues that both hyaluronic acid and recombinant collagen have their unique applications and benefits, and it is inappropriate to declare one superior to the other without substantial scientific evidence [31][32]. - The company emphasizes that the existing research favors hyaluronic acid in certain applications, particularly in skin hydration and immediate filling, while recombinant collagen may have advantages in tissue repair [31][32].

Core Viewpoint - The article discusses the controversy surrounding Huaxi Biological's rebuttal of the claims made by nine brokerage firms regarding hyaluronic acid being "outdated" and the promotion of recombinant collagen as a superior alternative, highlighting the impact of these claims on the market and the industry [2][4][9]. Group 1: Company Actions - Huaxi Biological publicly refuted the claims about hyaluronic acid and named nine brokerage firms for misleading reports, which has led to some brokerages retracting their reports and issuing apologies [2][8]. - The company received support from two industry associations before making its statement and has reported the matter to the China Securities Regulatory Commission [2][8]. - As of May 23, three of the ten reports mentioned have been removed from public access, while the remaining seven are still available for viewing [8][9]. Group 2: Industry Context - The medical beauty industry is characterized by a high overlap between capital market participants and enterprise users, making capital evaluations significantly impactful on the competitive landscape, which explains Huaxi Biological's strong response [2][4]. - The article emphasizes that the claims made in the brokerage reports lack scientific basis and are driven by speculative capital, which could harm a key industry in China [6][9][24]. Group 3: Scientific Claims - Huaxi Biological argues that the reports promoting recombinant collagen over hyaluronic acid are misleading and lack substantial scientific evidence, asserting that both substances have their unique benefits and should not be directly compared [23][24]. - The company highlights that the regulatory approvals for hyaluronic acid products far exceed those for recombinant collagen, indicating a stronger safety profile for hyaluronic acid [25][26]. Group 4: Regulatory Environment - The article notes that the regulatory environment for brokerage reports is tightening, with recent inspections revealing issues in compliance and the need for better management of report quality and information sources [18][20]. - There is a growing concern about the potential for misleading information in brokerage reports, which could lead to regulatory actions against the firms involved if found to be in violation of established guidelines [21][22].

Investment Rating - The report indicates a positive outlook for the banking sector, suggesting that certain stocks may have alpha potential due to policy catalysts and a cyclical recovery [4]. Core Insights - Multiple banks have lowered their deposit rates, with the one-year and five-year Loan Prime Rate (LPR) reduced by 10 basis points on May 20, 2025. This trend reflects a broader market-driven decline in deposit costs [1][2]. - The average deposit cost rate for China Merchants Bank decreased significantly by 25 basis points to 1.29% in Q1 2025, indicating a trend of improving deposit costs across the sector [1]. - The report highlights that banks like Chongqing Bank, Minsheng Bank, and CITIC Bank have substantial room for further deposit cost reductions, suggesting a favorable environment for banks to optimize their funding costs [2]. Summary by Sections Section 1: Focus of the Week - Several banks have adjusted their deposit rates downward, with over half of listed banks participating in this trend by May 24, 2025 [1]. - The report notes that the average deposit cost rate for China Merchants Bank has shown improvement since Q2 2024, aligning with previous forecasts of enhanced cost reduction in liabilities [1]. Section 2: Sector Perspective - The banking sector is expected to benefit from expansionary policies aimed at stabilizing the economy, with specific banks like Ningbo Bank, Postal Savings Bank, and China Merchants Bank highlighted as potential investment opportunities [4]. - The report emphasizes that the cyclical recovery may take time, but the ongoing interest rate cuts could sustain the dividend strategy for banks like Shanghai Bank and Jiangsu Bank [4]. Section 3: Key Data Tracking - The report tracks various financial metrics, including the issuance of interbank certificates and the average rates for different types of bank notes, indicating a dynamic market environment [9][8]. - It also notes the increase in the proportion of deposits with a remaining maturity of less than one year, which rose by 3 percentage points to 37.4% by the end of 2024, suggesting a trend towards concentrated deposit maturities [2][16].

每经记者｜杨建 每经编辑｜彭水萍 （一）重磅消息 5月24日，据"网信中国"微信公众号消息，近期，国家网信办会同金融管理部门依法处置一批散布资本 市场不实信息、开展非法荐股、炒作虚拟货币交易等的账号、网站。"爱股票App"等账号发布资本市场 不实信息。"侃哥说财经"等账号开展非法荐股。"火哥聊加密"等账号、网站宣传炒作虚拟货币交 易。"小北呦"等账号散布金融领域黑灰产信息。涉及的账号、网站已被依法依约关闭。 （二）券商最新研判 东方证券：沪综指震荡整固后，仍有潜力冲高3400点 1、近期持续强势的北交所股票突然下跌，从跌幅居前的北证50成分股来看，不少个股年内涨幅较大， 个股下跌实质是消化前期较大涨幅，投资者对此类涨幅较大个股要保持谨慎。当成长风格调整时，银行 板块就会充当市场定海神针，近日银行板块上涨，上海银行、成都银行等创出新高，本轮LPR利率、存 款利率等调降，整体息差影响偏积极，银行基本面有望持续稳健，板块高股息性价比凸显，值得稳健投 资者中长线持有。 2、从近几日题材热点来看，并购重组、创新药、固态电池、无人驾驶等表现相对稍强，但持续性有待 观察，显示市场并没有主流强势板块，符合调整市场表现，沪综指 ...

2025 年 5 月 22 日，公司兑付了 2024 年度第七期短期融资券本 息共计人民币 2,038,478,904.11 元。 特此公告。 西部证券股份有限公司董事会 2025 年 5 月 23 日 西部证券股份有限公司（以下简称"公司"）于 2024 年 6 月 19 日发行了公司 2024 年度第七期短期融资券，发行金额为人民币 20 亿 元，票面利率为 2.09%，发行期限为 336 天，兑付日为 2025 年 5 月 22 日。 | 证券代码：002673 证券简称：西部证券 | 公告编号：2025-038 | | --- | --- | | 债券代码：149949 | 债券简称：22西部06 | | 148177 | 23西部02 | | 148339 | 23西部03 | | 148391 | 23西部04 | | 148424 | 23西部05 | | 148699 | 24西部01 | | 148753 | 24西部02 | | 148865 | 24西部03 | | 148924 | 24西部04 | | 524008 | 24西部05 | | 524106 | 25西部01 | | 5 ...

在专业人士看来，《若干措施》通过强化多层次资本市场融资功能，优化融资环境、引导社会资本聚 集，推动北交所和新三板形成差异化发展。北交所作为服务创新型中小企业主阵地的地位进一步巩固， 而新三板则通过政策支持提升服务小微企业的能力。在规范且潜力十足的小微企业源源不断地输送至北 交所后，北证A股市场有望加速扩容。 据中国证监会首席风险官、发行监管司司长严伯进22日在国新办新闻发布会上介绍，私募股权创投基金 支持科技创新持续发力。其中，向战略性新兴产业的规模和占比持续提升，目前在投项目超过10万个， 在投本金超过4万亿元。 多层次市场助力小微企业 可以看到，《若干措施》着重发挥监管、货币、财税、产业等各项政策合力，从增加融资供给、降低综 合融资成本、提高融资效率、提高支持精准性、落实监管政策、强化风险管理、完善政策保障、做好组 织实施等8个方面，提出23项工作措施。 日前，金融监管总局、中国人民银行、中国证监会、国家发展改革委、工业和信息化部、财政部、税务 总局、市场监管总局等八部门联合印发了《支持小微企业融资的若干措施》（下称"《若干措施》"）， 旨在进一步改善小微企业、个体工商户融资状况。 《若干措施》指出，支持 ...